Lantheus Holdings, Inc. (LNTH)

Environment story

Lantheus Holdings operates as a radiopharmaceutical company with no disclosed direct manufacturing of fossil fuels, thermal power generation, or large-scale industrial emissions. The 10-K filing contains no explicit Scope 1, Scope 2, or Scope 3 emissions data, net-zero targets, renewable energy commitments, or environmental controversies. The company manufactures radiopharmaceuticals at facilities in North Billerica, Massachusetts and operates internationally; nuclear medicine production inherently involves radioactive materials but the filing does not disclose carbon footprint or climate mitigation strategies. No environmental lawsuits, fines, water-consumption disputes, or habitat-damage allegations are mentioned. The absence of disclosed climate commitments and emissions data results in standard deductions per deterministic rules.

Social story

Lantheus Holdings discloses minimal workforce demographic data in the 10-K filing. No CEO-to-median-worker pay ratio is disclosed; Brian Markison served as CEO until December 31, 2025, and Mary Anne Heino assumed the role on January 1, 2026 with no compensation comparisons provided. No turnover rate, plant safety records, union-suppression activities, strikes, or labor disputes are mentioned. No diversity percentages for women, underrepresented groups, or technical/executive leadership are disclosed in the filing. No supply-chain ethics audits, human-rights assessments, or conflict-minerals policies are referenced. The company operates manufacturing and R&D facilities in the United States, Canada, Germany, Switzerland, Sweden, and the United Kingdom; no allegations of labor violations or union activity are documented in the provided 10-K extract.

Governance story

Lantheus Holdings' governance structure is not fully detailed in the provided 10-K extract. Board composition and independence percentages are not disclosed. Share structure is described as common stock with a repurchase program authorized through December 31, 2027 ($400 million capacity); no dual-class voting structure is mentioned. No lobbying expenditure disclosures, antitrust proceedings, SEC consent decrees, privacy fines, or significant regulatory actions are documented in the filing. The company discloses recent leadership transitions (Mary Anne Heino appointed Executive Chair in November 2025, CEO January 1, 2026) and Board approval of strategic business transactions (SPECT business sale, Life Molecular Imaging acquisition, licensing agreements). No shareholder litigation, proxy contests, or activist campaigns are mentioned. The absence of disclosed lobbying spend, regulatory fines, and antitrust actions results in no deductions beyond standard governance assessment.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Lantheus Holdings, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Lantheus Holdings, Inc. in the app for interactive charts and portfolio building.

More in Healthcare